PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.
Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.